Articles related to ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone(hyper-CVAD) regimen has undergone many modifications to make administration more palatable and user-friendly for patients and physicians in community and academic settings, including refinements to avoid complications and reduce adverse events. Dr. Elias Jabbour of MD Anderson Cancer Center reviews a number of these modifications in this interview.

Overall, NGS-based MRD analysis in ALL seems to be especially helpful in patients with RQ-PCR+ MolNE and may help to discriminate true MRD from false positivity in this considerable and clinically important group.

Perelman School of Medicine’s David Teachey, MD, reviews outcomes and implications from two recent Children’s Oncology Group trials and describes current research with daratumumab and CAR T-cell therapy.

Patients with T-LL had significantly improved EFS and OS with bortezomib on the AALL1231 backbone. Systemic therapy intensification allowed elimination of CRT in more than 90% of patients with T-ALL without excess relapse. There was no difference in rates of receiving CRT.